Clinical Trials on Baetz-Greenwalt Syndrome

Total 33923 results

Astex Pharmaceuticals, Inc.

Terminated

A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

United States
Novartis Pharmaceuticals

Active, not recruiting

A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS). (STIMULUS-MDS1)

Myelodysplastic Syndromes

Czechia, Hungary, Japan, Taiwan, United States, Belgium, Italy, United Kingdom, Korea, Republic of, Hong Kong, Austria, Germany, Turkey, Spain, Greece, France, Canada
Shanghai Antengene Corporation Limited

Terminated

A Study to Evaluating the Pharmacokinetics, Safety, and Efficacy of ATG 016 Monotherapy in IPSS-R Intermediate Risk and Above Myelodysplastic Syndrome (MDS) (HATCH)

Myelodysplastic Syndrome

China
Washington University School of Medicine
Jazz Pharmaceuticals

Active, not recruiting

CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents

Myelodysplastic Syndrome

United States
Eisai Inc.

Completed

Escalation Study to Determine Bioavailability of a Single Oral Dose of Decitabine in Patients With Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States
Fundación General de la Universidad de Salamanca
Celgene Corporation

Completed

Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome (SINTRA-REV)

Myelodysplastic Syndrome

Germany, Spain, France
Sumitomo Pharma Co., Ltd.

Completed

Study of DSP-7888 in Patients With Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

Japan
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center; Columbia University; Karyopharm Therapeutics Inc

Completed

Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Columbia University
Celgene Corporation

Active, not recruiting

Revlimid in Transfusion Dependent Patients

Myelodysplastic Syndrome

United States
Montefiore Medical Center
Albert Einstein College of Medicine

Withdrawn

Pyrimethamine for Intermediate/High-risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

United States
Onconova Therapeutics, Inc.

Completed

Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs

Myelodysplastic Syndromes

United States, France, Germany
Boehringer Ingelheim

Terminated

Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States, Germany
Array Biopharma, now a wholly owned subsidiary...

Completed

A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome

Myelodysplastic Syndromes

United States
Onconova Therapeutics, Inc.

Withdrawn

Three Dosing Schedules of Oral Rigosertib in MDS Patients

Myelodysplastic Syndrome

United States
PersImmune, Inc
University of California, San Diego

Unknown

Personalized Adoptive Cellular Therapy Targeting MDS Stem Cell Neoantigens (PACTN)

Myelodysplastic Syndromes

United States
Celgene

Completed

Alternative Dosing Regimens of Subcutaneous Azacitidine for Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
GlaxoSmithKline
Parexel

Terminated

Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes | Myelodysplastic Syndrome

United States, Spain
MedImmune LLC

Completed

Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States, United Kingdom, France, Germany
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

RAD001(Everolimus) in Treating Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Opsona Therapeutics Ltd.
M.D. Anderson Cancer Center; Montefiore Medical Center; New York Presbyterian... and other collaborators

Completed

A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States
Opsona Therapeutics Ltd.
M.D. Anderson Cancer Center; Montefiore Medical Center; New York Presbyterian... and other collaborators

Completed

Follow up Protocol to the Phase I/II Study of OPN-305 in Second-line or Third-line Lower Lower Risk Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center
Genzyme, a Sanofi Company

Completed

Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Amifostine in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes

United States
Sunnybrook Health Sciences Centre
Novartis

Terminated

Azacitidine Plus Deferasirox (ICL670) in Higher Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

Canada
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé Et de la Recherche Médicale, France; Gustave... and other collaborators

Completed

Prospective Study of Molecular Predictors of Survival in Myelodysplastic Syndromes (MDS04)

Myelodysplastic Syndromes

France
Institut Paoli-Calmettes

Unknown

Evaluation of a Question Prompt List for Patients With Myelodysplastic Syndromes (QPL-MDS) (QPL-MDS)

Myelodysplastic Syndromes

France
Celgene

Completed

Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes

Myelodysplastic Syndrome

United States
SymBio Pharmaceuticals

Completed

Long Term Safety Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study

Myelodysplastic Syndrome

Japan
SymBio Pharmaceuticals

Completed

Long Term Safety Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study

Myelodysplastic Syndrome

Japan
Hoffmann-La Roche

Completed

A Study of NeoRecormon (Epoetin Beta), CellCept (Mycophenolate Mofetil) and Prednisone in Patients With Low or Intermediate Myelodysplastic Syndromes.

Myelodysplastic Syndromes

Spain
Roswell Park Cancer Institute
Genzyme, a Sanofi Company

Terminated

Safety and Tolerability of Oral Clofarabine in Intermediate to High Risk Myelodysplastic Patients

Myelodysplastic Syndrome

United States
University of Rochester

Completed

Bortezomib in Treating Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
TetraLogic Pharmaceuticals

Completed

Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy

Myelodysplastic Syndrome

United States
Washington University School of Medicine

Completed

Lenalidomide for Myelodysplastic Syndrome Refractory to Hypomethylating Agents

Myelodysplastic Syndromes

United States
Seoul St. Mary's Hospital
Celgene Corporation

Unknown

5 Day Versus 7 Day Azacitidine in Lower Risk Myelodysplastic Syndrome

Myelodysplastic Syndrome

Korea, Republic of
Eisai Inc.

Terminated

A Clinical Trial of Decitabine in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States
Janssen Korea, Ltd., Korea

Completed

An Observational Study for Dacogen Long-Term Treatment in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes

Korea, Republic of
Technische Universität Dresden
Wyeth is now a wholly owned subsidiary of Pfizer

Terminated

Temsirolimus in Myelodysplastic Syndrome (MDS) (TEMDS)

Myelodysplastic Syndrome

Germany
Bioniche Pharma USA LLC

Completed

Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients

Myelodysplastic Syndrome

United States, France
Università degli Studi di Brescia
University of Bologna; University of Udine; University of Genova; University of... and other collaborators

Completed

5-Azacitidine in Low-risk Myelodysplastic Syndromes (MDSs) (MDSAZA0706)

Myelodysplastic Syndrome

Italy
Rush University Medical Center
H. Lundbeck A/S

Terminated

Phase 2, Open-Label, Multi-Dose Study of Panhematin in Patients With MDS

Myelodysplastic Syndrome

United States
Janssen Research & Development, LLC

Terminated

A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States, Belgium, Spain, Australia, Sweden, Netherlands, Russian Federation
Arno Therapeutics

Unknown

Study of AR-67 (DB-67) in Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States
Groupe Francophone des Myelodysplasies
EpiCept Corporation

Withdrawn

Azacitidine With or Without Ceplene/Interleukin-2 in Patients With Higher Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes

France
Groupe Francophone des Myelodysplasies
Roche Pharma AG; Celgene Corporation

Completed

Azacitidine Combined to Epoetin Beta in International Prognostic Scoring System (IPSS) Low-risk and Intermediate-1 Myelodysplastic Syndrome (MDS) Patients, Resistant to Erythropoetin-stimulating Agents (ESA)

Myelodysplastic Syndromes

France
Samsung Medical Center

Unknown

Platelet Response During the Second Cycle of Decitabine Can Predict Response and Survival for Myelodysplastic Syndrome

Myelodysplastic Syndrome

Korea, Republic of
Cttq

Unknown

A Phase Ⅳ Study of Decitabine in Myelodysplastic Syndrome (DREAM)

Myelodysplastic Syndrome

China
Northwestern University
Robert H. Lurie Cancer Center

Terminated

Phase I/II Trial of Sodium Stibogluconate in Myelodysplastic Syndrome

Myelodysplastic Syndromes

United States
Fondazione Italiana Sindromi Mielodisplastiche-ETS

Withdrawn

Study of Clofarabine in Combination With Low Dose Cytarabine to Treat Myelodysplastic Syndromes (CLO2009AISSM05)

Myelodysplastic Syndromes

Italy

Clinical Trials on Baetz-Greenwalt Syndrome

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United States

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations